The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Open accessAbstract
The ability to proliferate independently of signals from other cell types is a fundamental characteristic of tumor cells. Using a 3D culture model of human breast cancer progression, we have delineated a protease-dependent autocrine loop that provides an oncogenic stimulus in the absence of proto-oncogene mutation. Targeting this protease, TNF-alpha-converting enzyme (TACE; also referred to as a disintegrin and metalloproteinase 17 [ADAM17]), with small molecular inhibitors or siRNAs reverted the malignant phenotype in a breast cancer cell line by preventing mobilization of 2 crucial growth factors, TGF-alpha and amphiregulin. We show that TACE-dependent ligand shedding was prevalent in a series of additional breast cancer cell lines and, in all cases examined, was amenable to inhibition. Using existing patient outcome data, we demonstrated a strong correlation between TACE and TGFA expression in human breast cancers that was predictive of poor prognosis. Tumors resulting from inappropriate activation of the EGFR were common in multiple tissues and were, for the most part, refractory to current targeted therapies. The data presented here delineate the molecular mechanism by which constitutive EGFR activity may be achieved in tumor progression without mutation of the EGFR itself or downstream pathway components and suggest that this important oncogenic pathway might usefully be targeted upstream of the receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
An Essential Role for Ectodomain Shedding in Mammalian Development
Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., Russell, W. E., Castner, B. J., Johnson, R. S., Fitzner, J. N., et al. (1998) · Science · doi:10.1126/science.282.5392.1281 · Cited by 1,607
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
Self-citationCloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378
Petersen, O. W., Rønnov-Jessen, L., Howlett, A. R., & Bissell, M. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9064 · Cited by 1,094
Self-citationDistinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
Sahin, U., Weskamp, G., Kelly, K., Zhou, H.-M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., & Blobel, C. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307137 · Cited by 979
Buxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., & Black, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27765 · Cited by 934
EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
Tanoue, L. T. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70092-6 · Cited by 776
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Self-citationLuetteke, N. C., Qiu, T. H., Fssssenton, S. E., Troyer, K. L., Riedel, R. F., Chang, A., & Lee, D. C. (1999) · Development · doi:10.1242/dev.126.12.2739 · Cited by 567
Zhou, B.-B. S., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 374
Shoyab, M., McDonald, V. L., Bradley, J. G., & Todaro, G. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6528 · Cited by 363
TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells
Gschwind, A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg231 · Cited by 342
Sternlicht, M. D., Sunnarborg, S. W., Kouros-Mehr, H., Yu, Y., Lee, D. C., & Werb, Z. (2005) · Development · doi:10.1242/dev.01966 · Cited by 309
Tumor Necrosis Factor-α-converting Enzyme Is Required for Cleavage of erbB4/HER4
Rio, C., Buxbaum, J. D., Peschon, J. J., & Corfas, G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10379 · Cited by 309
Dı́az-Rodrı́guez, E., Montero, J. C., Esparı́s-Ogando, A., Yuste, L., & Pandiella, A. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-11-0561 · Cited by 308
Tissue structure, nuclear organization, and gene expression in normal and malignant breast.
Bissell, M. J., Weaver, V. M., Lelièvre, S. A., Wang, F., Petersen, O. W., & Schmeichel, K. L. (1999) · PubMed · Cited by 297
Self-citationTACE is required for the activation of the EGFR by TGF-α in tumors
Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., & Arribas, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg111 · Cited by 274
Wang, F., Hansen, R. K., Radisky, D., Yoneda, T., Barcellos-Hoff, M. H., Petersen, O. W., Turley, E. A., & Bissell, M. J. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1494 · Cited by 270
Self-citationWiesen, J. F., Young, P., Werb, Z., & Cunha, G. R. (1999) · Development · doi:10.1242/dev.126.2.335 · Cited by 266
Briand, P., Petersen, O. W., & Deurs, B. (1987) · In Vitro Cellular & Developmental Biology · doi:10.1007/bf02623578 · Cited by 240
Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs
Franzke, C.-W., Tasanen, K., Schäcke, H., Zhou, Z., Tryggvason, K., Mauch, C., Zigrino, P., Sunnarborg, S., Lee, D. C., Fahrenholz, F., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf532 · Cited by 230
Bergmeier, W., Piffath, C. L., Cheng, G., Dole, V. S., Zhang, Y., von Andrian, U. H., & Wagner, D. D. (2004) · Circulation Research · doi:10.1161/01.res.0000143899.73453.11 · Cited by 226
Erlotinib in-Previously Treated Non-Small-Cell Lung Cancer
Hanna, N. H. (2006) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70163-5 · Cited by 207
Schäfer, B., Marg, B., Gschwind, A., & Ullrich, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400129200 · Cited by 168
Zhang, Y., Jiang, J., Black, R. A., Baumann, G. P., & Frank, S. J. (2000) · Endocrinology · doi:10.1210/endo.141.12.7858 · Cited by 140
Briand, P., Nielsen, K. V., Madsen, M. W., & PETERSEN, O. W. (1996) · PubMed · Cited by 118
Zhang, Y., Hegen, M., Xu, J. Y., Keith, J. C., Jin, G., Du, X., Cummons, T. A., Sheppard, B. J., Sun, L., Zhu, Y., et al. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.08.003 · Cited by 57
Beck, G., Bottomley, G. A., Bradshaw, D. J., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.390 · Cited by 52
Garton, K. J., Ferri, N., & Raines, E. W. (2002) · BioTechniques · doi:10.2144/02324rr01 · Cited by 49
Cited by
EDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Nuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Metadata
- Authors
- Kenny, P. A., & Bissell, M. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-02-01
- Volume
- 117
- Issue
- 2
- Pages
- 337-345
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2116561160
- Cited by
- 252
- References
- 44
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.